DDInter1783 DDInter1435
Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells. The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Tetracycline {u} (Compound) resembles {v} (Compound) Demeclocycline
Tetracycline {u} (Compound) binds {v} (Gene) ALB
Tetracycline {u} (Compound) is included by {v} (Pharmacologic Class) Tetracyclines
Tetracycline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Diclofenamide
Tetracycline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Triamterene
Tetracycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium carbonate
Tetracycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digoxin
Tetracycline {u} may lead to a major life threatening interaction when taken with {v} Methoxyflurane
Tetracycline {u} may lead to a major life threatening interaction when taken with {v} Acitretin
Tetracycline (Compound) resembles Demeclocycline (Compound)
Tetracycline (Compound) binds ALB (Gene)
Tetracycline (Compound) is included by Tetracyclines (Pharmacologic Class)
Tetracycline may cause a minor interaction that can limit clinical effects when taken with Diclofenamide
Tetracycline may cause a minor interaction that can limit clinical effects when taken with Triamterene
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin
Tetracycline may lead to a major life threatening interaction when taken with Methoxyflurane
Tetracycline may lead to a major life threatening interaction when taken with Acitretin